Free Trial
NASDAQ:STOK

Stoke Therapeutics (STOK) Stock Price, News & Analysis

Stoke Therapeutics logo
$11.55 -0.10 (-0.86%)
Closing price 07/2/2025 04:00 PM Eastern
Extended Trading
$11.64 +0.09 (+0.78%)
As of 04:02 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Stoke Therapeutics Stock (NASDAQ:STOK)

Key Stats

Today's Range
$11.32
$11.86
50-Day Range
$8.66
$11.84
52-Week Range
$5.35
$16.15
Volume
403,403 shs
Average Volume
670,362 shs
Market Capitalization
$630.63 million
P/E Ratio
14.62
Dividend Yield
N/A
Price Target
$23.20
Consensus Rating
Buy

Company Overview

Stoke Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
81st Percentile Overall Score

STOK MarketRank™: 

Stoke Therapeutics scored higher than 81% of companies evaluated by MarketBeat, and ranked 225th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Stoke Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.29, and is based on 5 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Stoke Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about Stoke Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Stoke Therapeutics are expected to decrease in the coming year, from ($2.01) to ($2.27) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Stoke Therapeutics is 14.62, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.22.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Stoke Therapeutics is 14.62, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 26.17.

  • Price to Book Value per Share Ratio

    Stoke Therapeutics has a P/B Ratio of 2.67. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Stoke Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    24.51% of the float of Stoke Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Stoke Therapeutics has a short interest ratio ("days to cover") of 16, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Stoke Therapeutics has recently increased by 0.67%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Stoke Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Stoke Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    24.51% of the float of Stoke Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Stoke Therapeutics has a short interest ratio ("days to cover") of 16, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Stoke Therapeutics has recently increased by 0.67%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Stoke Therapeutics has a news sentiment score of 0.31. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.90 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Stoke Therapeutics this week, compared to 5 articles on an average week.
  • Search Interest

    2 people have searched for STOK on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    Only 4 people have added Stoke Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Stoke Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $82,354.00 in company stock.

  • Percentage Held by Insiders

    Only 9.50% of the stock of Stoke Therapeutics is held by insiders.

  • Read more about Stoke Therapeutics' insider trading history.
Receive STOK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stoke Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

STOK Stock News Headlines

A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Stockley named Stoke's new academy manager
STOK Stoke Therapeutics, Inc. - Seeking Alpha
See More Headlines

STOK Stock Analysis - Frequently Asked Questions

Stoke Therapeutics' stock was trading at $11.03 at the beginning of 2025. Since then, STOK stock has increased by 4.7% and is now trading at $11.55.
View the best growth stocks for 2025 here
.

Stoke Therapeutics, Inc. (NASDAQ:STOK) announced its quarterly earnings results on Monday, March, 24th. The company reported ($0.18) EPS for the quarter, topping analysts' consensus estimates of ($0.56) by $0.38. The firm had revenue of $22.61 million for the quarter, compared to analyst estimates of $4.20 million. Stoke Therapeutics had a net margin of 26.33% and a trailing twelve-month return on equity of 19.08%.

Stoke Therapeutics (STOK) raised $100 million in an IPO on Wednesday, June 19th 2019. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

Shares of STOK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Stoke Therapeutics investors own include Enovix (ENVX), Rambus (RMBS), COMPASS Pathways (CMPS), Globant (GLOB), Ginkgo Bioworks (DNA), Toast (TOST) and Saia (SAIA).

Company Calendar

Last Earnings
3/24/2025
Today
7/02/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:STOK
Fax
N/A
Employees
100
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$23.20
High Stock Price Target
$35.00
Low Stock Price Target
$17.00
Potential Upside/Downside
+100.9%
Consensus Rating
Buy
Rating Score (0-4)
3.29
Research Coverage
7 Analysts

Profitability

Trailing P/E Ratio
14.62
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$88.98 million
Pretax Margin
27.00%

Debt

Sales & Book Value

Annual Sales
$36.56 million
Price / Cash Flow
N/A
Book Value
$4.32 per share
Price / Book
2.67

Miscellaneous

Free Float
49,410,000
Market Cap
$630.63 million
Optionable
Optionable
Beta
1.14
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NASDAQ:STOK) was last updated on 7/3/2025 by MarketBeat.com Staff
From Our Partners